Big Beat for Gilead on Rising Sovaldi Revenue

July 23 (Bloomberg) -- Gilead Sciences, maker of the hepatitis C pill Sovaldi, doubled its sales forecast for the year on better-than-estimated revenue from the blockbuster pill. Bloomberg’s Olivia Sterns reports on “Street Smart.” (Source: Bloomberg)
Should Investors Focus on Facebook’s Active Users?
37:03 - Techonomy Founder David Kirkpatrick, Jun Group CEO Mitchell Reichgut and Sprinklr General Manager Simon Mansell examine Facebook user growth and advertising revenue. They speak with Bloomberg’s Emily Chang on “Bloomberg West.” (Source: Bloomberg)
  • Facebook Has Solid Numbers Across the Board: Pyykkonen
  • Hatzius, Blinder See 'Baby Step' in Fed Policy Statement
  • Is Facebook Being Hurt by the Stronger Dollar?